Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2100 • ACR Convergence 2023
Paradoxical Antagonistic Association of Visceral and Subcutaneous Adipose Tissue with Circulating C-Reactive Protein in Rheumatoid Arthritis
Jon Giles and Joan Bathon, Columbia University, New York, NY
Background/Purpose: C-reactive protein (CRP) is used as an indicator of disease activity in people with RA.However, adipose tissue also expresses inflammatory cytokines that induce hepatic…
Abstract Number: 2117 • ACR Convergence 2023
Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis
Sayuli Bhide¹, Punyasha Roul², Namrata Singh³, Grant Cannon⁴, Gary Kunkel⁵, Ted R Mikuls⁶, Bryant England², Dolores Shoback⁷, Patti Katz⁸, Jose Garcia⁹, Ariela Orkaby¹⁰, Joshua Baker¹¹ and K Wysham¹², ¹University of Washington, Seattle, WA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁷San Francisco VA Medical Center, San Francisco, CA, ⁸University of California San Francisco, San Rafael, CA, ⁹VA Puget Sound Healthcare System, Seattle, WA, ¹⁰Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Frailty is established as an important predictor of mortality in the general population.1Rheumatoid arthritis (RA) is associated with higher rates of frailty than the…
Abstract Number: 2133 • ACR Convergence 2023
Cardiovascular Risk Factors Are Associated with Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results from the OBRI
Samar Aboulenain¹, Xiuying Li², Mohammad Movahedi³, Claire Bombardier¹ and Bindee Kuriya¹, ¹University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Cardiovascular (CVD) comorbidity can impact overall RA care. We demonstrated that CVD risk factors were associated with higher disease activity and disability. Here, we…
Abstract Number: 2149 • ACR Convergence 2023
Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors
Yuriko Yamamura¹, Kieran Woolcock², Valerie Corrigall³, Lara Ravanetti⁴, Jorge De Alba⁴, Roly Foulkes⁵, Paul Eggleton⁶ and Carl Goodyear², ¹School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Revolo Biotherapeutics, Tadworth, United Kingdom, ⁴Revolo Biotherapeutics, London, United Kingdom, ⁵Revolo Biotherapeutics, Slough, United Kingdom, ⁶Revolo Biotherapeutics, Exeter, United Kingdom
Background/Purpose: IRL201805 is a novel biologic derived from Binding Immunoglobulin Protein (BiP) that has been developed for the treatment of Rheumatoid arthritis (RA) (P Eggleton,…
Abstract Number: 2166 • ACR Convergence 2023
Long-Term Effects of Abatacept on Arthritis and Atherosclerosis in Older vs Younger Patients with Rheumatoid Arthritis: 3-year Results of a Prospective, Multicenter, Observational Study
Zento Yamada¹, Sei Muraoka¹, Mai Kawazoe², Wataru Hirose³, Hajime Kono⁴, Shinsuke Yasuda⁵, Takahiko Sugihara⁶ and Toshihiro Nanki², ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ³Hirose Clinic of Rheumatology, Saitama, Japan, ⁴Teikyo University School of Medicine, Tokyo, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁶Toho University, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease secondary to atherosclerosis. Although it has been reported that TNF inhibitor…
Abstract Number: 2434 • ACR Convergence 2023
Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response
Mikhail Volkov, Arieke Kampstra, Karin van Schie, Joanneke Kwekkeboom, Arnoud de Ru, Peter van Veelen, Thomas Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Gut-residing bacteria, such as E.coli, can acetylate their proteome under conditions of amine starvation. It is postulated that the (gut) microbiome is involved in…
Abstract Number: 2507 • ACR Convergence 2023
ZCCHC6 Modulates the Global Phosphorylation Landscape in TNF-a-induced Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: ZCCHC6, also known as TUT7 or TENT2, plays a crucial role in RNA processing and metabolism through its uridylyl transferase function. This function involves…
Abstract Number: 2592 • ACR Convergence 2023
Trends, Sociodemographic and Clinical Factors Associated with Avascular Necrosis and Related Arthroplasties in Hospitalized Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Rashmi Dhital¹, Neha Singh², Brian Pedersen² and Christie M. Bartels³, ¹UC San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Avascular necrosis (AVN) can be a debilitating complication of autoimmune diseases and steroid treatment, with a higher prevalence in systemic lupus erythematosus (SLE) (0.8-33%)…
Abstract Number: 0013 • ACR Convergence 2023
A Proliferating T Cell Signature in Blood Is Associated with Response to JAK Inhibitor Therapy in Rheumatoid Arthritis Patients
Mehreen Elahee¹, Kathryne Marks², Ifeoluwakiisi Adejoorin², Lin Chen², Derrick Todd², Jonathan Coblyn², Elena Massarotti², Susan Ritter², Michael Weinblatt³, Daniel Solomon⁴ and Deepak Rao², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Waban, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: There are multiple DMARDs available to treat rheumatoid arthritis (RA) yet there are no widely used predictive biomarkers to guide selection of a specific…
Abstract Number: 0078 • ACR Convergence 2023
Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Are Elevated in Patients with Rheumatoid Arthritis and Predict Treatment Response to Abatacept or TNF Blockers
Maria-Eugenia Miranda-Carus¹, Beatriz Nieto-Carvalhal¹, Irene Monjo², Mariela Uyaguari-Morocho¹, Alejandro Villalba³, Laura Nuño¹, Diana Peiteado¹, Elisa Fernández¹, Sara García-Carazo¹ and Alejandro Balsa⁴, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²University Hospital La Paz, Madrid, Spain, ³Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: CD4+CXCR5+PD-1hi follicular helper (Tfh) T cells dwell in the germinal centers (GCs), help B cells, and are implicated in Rheumatoid Arthritis (RA) pathogenesis. Circulating…
Abstract Number: 0216 • ACR Convergence 2023
High Immunogenicity of mRNA Covid-19 Vaccine Booster in Immune Mediated Inflammatory Disease
Rebecca Haberman¹, Rebecca Blank², Paula Rackoff², Gary Solomon³, Samrachana Adhikari¹, Natalie Azar⁴, Ramin Herati¹, Pamela Rosenthal⁵, Peter Izmirly⁶, Jonathan Samuels⁷, Brian Golden⁸, Soumya Reddy⁵, Mark Mulligan¹ and Jose Scher⁶, ¹NYU Grossman School of Medicine, New York, NY, ²New York University, New York, NY, ³NYU Langone School of Medicine, Hartsdale, NY, ⁴NYU Langone, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Langone, Rye Brook, NY, ⁸NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Patients with immune-mediated inflammatory disorders (IMIDs) have an inherently heightened susceptibility to infection and may be considered high risk for COVID-19, yet IMID populations…
Abstract Number: 0382 • ACR Convergence 2023
Heterogeneity Within a “difficult to Treat” Rheumatoid Arthritis Patients Cohort: 36% May Have a More Benign Course and Have Distinct Characteristics at bDMARD or tsDMARD Initiation
Irini Flouri¹, Antonios Bertsias², Argyro Repa², Nestor Avgoustidis², Eleni Kalogiannaki², Sofia Pitsigavdaki³, George Bertsias⁴ and Prodromos Sidiropoulos⁴, ¹University of Crete Medical School, Heraklion, Greece, ²Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, ³Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, ⁴Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece
Background/Purpose: Early detection of difficult to treat (D2T) RA patients as well as better characterization of their long-term course represent unresolved issues. Herein we aimed…
Abstract Number: 0398 • ACR Convergence 2023
Identification of Disease Activity-related miRNAs Through Artificial Neural Network Analysis in Rheumatoid Arthritis
Milena Rodriguez Alvarez¹, Lissette Delgado-Cruzata², Anna Tryfonos¹, Nickolas Almodovar², Toni-Ann Bravo² and Naureen Kabani¹, ¹SUNY Downstate Health Sciences University, Brooklyn, NY, ²The City University of New York, John Jay College, New York, NY
Background/Purpose: Rheumatoid Arthritis (RA) is the result of the complex interplay between genetic, epigenetic, and environmental factors leading to immune dysregulation, synovial membrane inflammation, and…
Abstract Number: 0415 • ACR Convergence 2023
Serious Infections Hospital Admissions and Mortality in Patients with Early Inflammatory Arthritis: Results from a Large UK Cohort
Maryam Adas¹, Bechman Katie¹, Mark Russell¹, Ioasaf Karafotias¹, Deepak Nagra¹, Sam Norton¹, Mark Garton² and James Galloway¹, ¹King's College London, London, United Kingdom, ²The Shrewsbury and Telford hospital NHS trust, Shropshire, United Kingdom
Background/Purpose: To identify risk of serious infections (SI) according to initial treatment strategy, using conventional synthetic disease modifying anti-rheumatic drugs (csDMARD) and corticosteroids, in patients…
Abstract Number: 0432 • ACR Convergence 2023
Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice
Rodolfo Perez-Alamino¹, Carolina Isnardi², Enrique Soriano³, Luciano Lo Giudice⁴, johana zacariaz hereter⁴, Gustavo Casado⁵, Victor Caputo⁵, Andrea Schmichowski⁵, Cecilia Romeo⁵, Estela Rivero⁵, Florencia Savy⁶, Mercedes García⁷, Olga Romano¹, Hernan Maldonado Ficco⁸ and Gustavo Citera², ¹Hospital Avellaneda, Tucuman, Argentina, ²IREP, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Militar Central, Buenos Aires, Argentina, ⁶HIGA San Martin, La Plata, Argentina, ⁷Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁸Hospital San Antonio de Padua, Río Cuarto, Argentina
Background/Purpose: Different guidelines recommend the use of tofacitinib either in monotherapy or combined with methotrexate (combination therapy) in patients with rheumatoid arthritis (RA) with an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].